New drugs for the treatment of Mycobacterium tuberculosis infection

ALMATAR M., ALMANDEAL H., VAR I., KAYAR B., KÖKSAL F.

BIOMEDICINE & PHARMACOTHERAPY, cilt.91, ss.546-558, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 91
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.biopha.2017.04.105
  • Dergi Adı: BIOMEDICINE & PHARMACOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.546-558
  • Anahtar Kelimeler: Tuberculosis, Antitubercular agents, Novel drugs, Antibiotic, Clinical trials, Mode of action, MULTIDRUG-RESISTANT TUBERCULOSIS, HOST-DIRECTED THERAPIES, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, ADJUNCTIVE THALIDOMIDE THERAPY, TETRAMIC ACID-DERIVATIVES, CELL-WALL CORE, IN-VITRO, COENZYME F-420, BACTERICIDAL ACTIVITY, ANTITUBERCULAR DRUG
  • Çukurova Üniversitesi Adresli: Evet

Özet

Tuberculosis presents a grave challenge to health, globally instigating 1.5 million mortalities each year. Following the breakthrough of first-line anti-TB medication, the number of mortalities reduced greatly; nonetheless, the swift appearance of tuberculosis which was drug-resistant, as well as the capability of the bacterium to survive and stay dormant are a considerable problem for public health. In order to address this issue, several novel possible candidates for tuberculosis therapy have been subjected to clinical trials of late. The novel antimycobacterial agents are acquired from different categories of medications, operate through a range of action systems, and are at various phases of advancement. We therefore talk about the present methods of treating tuberculosis and novel anti-TB agents with their action method, in order to advance awareness of these new compounds and medications. (C) 2017 Elsevier Masson SAS. All rights reserved.